ANGELA SANDERS: Open Payments
NPI 1407256613 · DANVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,493 in 105 payments from 36 companies in 2025. Trend: 2023 $3,048 · 2024 $2,421 · 2025 $2,493
Food & beverage: $2,209Education: $285
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 14 | $390 |
| Novartis Pharmaceuticals Corporation | 21 | $333 |
| PFIZER INC. | 10 | $170 |
| Merck Sharp & Dohme LLC | 7 | $164 |
| Eisai Inc. | 8 | $164 |
| Amgen Inc. | 2 | $111 |
| SEAGEN INC. | 1 | $100 |
| ABBVIE INC. | 4 | $88 |
| SOBI, INC | 1 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $82 |
Products named: KISQALI, Lenvima, KEYTRUDA, LUMAKRAS, REBLOZYL, SCEMBLIX, VENCLEXTA, ELREXFIO.
Industry payments across IN — which companies pay providers there.
